AIHealthcare Analytics

Knowledge Wiki

Wiki › FDA TEMPO Pilot — Generative AI Medical Devices Path to Patients Before Authorization (Updated 2026)

FDA TEMPO Pilot — Generative AI Medical Devices Path to Patients Before Authorization (Updated 2026)

CONCEPT
Rev 5 Oct 10, 2026 09:37 UTC 1 sources

FDA's TEMPO (Total Product Life Cycle Advisory Program) pilot represents an innovative regulatory approach allowing generative AI medical devices to reach patients before full pre-market authorization, with post-market surveillance and evidence collection. This pathway accelerates patient access to AI devices while maintaining safety oversight through continuous monitoring and evidence generation. It represents a shift from traditional pre-market validation toward adaptive post-market evaluation. The TEMPO approach reflects FDA recognition that traditional pre-market evidence standards may be inappropriate for AI systems that improve continuously and adapt to new clinical contexts. --- ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index